Objectives: The aim of this study was to assess the diagnostic usefulness of vascular endothelial growth factor (VEGF) and endostatin mRNA in cervical specimens of patients with cervical dysplasia and carcinoma. Study Design: Transcription levels of VEGF and endostatin were detected by RT-PCR in cervical liquid-based preparation specimens and compared with cytological assessments. Results: VEGF as well as endostatin mRNA expression was significantly associated with either cytological or histological diagnosis (p < 0.05). VEGF mRNA and endostatin mRNA were significantly more likely to be expressed in squamous cell carcinomas (SCC) than in cervical intraepithelial neoplasia (CIN) III (p < 0.01 and p < 0.05), and obviously also more likely to be expressed in CINII than in CINI and in CINIII than in CINII (p < 0.05). Eleven inflammation lesions gave positive results by cytology but negative results by RT-PCR for VEGF and endostatin mRNA. Twenty-four SCC lesions gave false-negative or precancerous lesion results by cytology but positive results by RT-PCR for VEGF and/or endostatin mRNA expression. Conclusion: Transcription levels of VEGF and endostatin by RT-PCR may be an adjunct to cytology screening for early detection of cervical carcinomas and may determine the progressive potentiality of individual lesions, especially in high-risk patients.

1.
Zhang Q, Zhang Y, Wang SZ, Wang N, Jiang WG, Ji YH, Zhang SL: Reduced expression of tissue factor pathway inhibitor-2 contributes to apoptosis and angiogenesis in cervical cancer. J Exp Clin Cancer Res 2012;31:1.
2.
Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-265.
3.
Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000;407:249-257.
4.
Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-1027.
5.
Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF, Brown LF: Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995;87:1237-1245.
6.
Fujiwaki R, Hata K, Iida K, Maede Y, Miyazaki K: Vascular endothelial growth factor expression in progression of cervical cancer: correlation with thymidine phosphorylase expression, angiogenesis, tumor cell proliferation, and apoptosis. Anticancer Res 2000;20:1317-1322.
7.
Kodama J, Seki N, Tokumo K, Hongo A, Miyagi Y, Yoshinouchi M, Okuda H, Kudo T: Vascular endothelial growth factor is implicated in early invasion in cervical cancer. Eur J Cancer 1999;35:485-489.
8.
Lee IJ, Park KR, Lee KK, Song JS, Lee KG, Lee JY, Cha DS, Choi HI, Kim DH, Deung YK: Prognostic value of vascular endothelial growth factor in stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 2002;54:768-779.
9.
Toussaint-Smith E, Donner DB, Roman A: Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene 2004;23:2988-2995.
10.
Chen W, Li F, Mead L, White H, Walker J, Ingram DA, Roman A: Human papillomavirus causes an angiogenic switch in keratinocytes which is sufficient to alter endothelial cell behavior. Virology 2007;367:168-174.
11.
Lee DW, Kim YT, Kim SW, Kim S, Kim JH, Kang MH, Hwang JH, Lim J: Expression of interleukin-5 and tumor necrosis factor alpha in cervical carcinoma. Clin Vaccine Immunol 2009;16:959-961.
12.
Landt S, Heidecke H, Reuter C, Korlach S, Blohmer JU, Lichtenegger W, Heusner T, Stöblen F, Thill M, Barinoff J, Sehouli J, Kümmel S: The utility of an in vitro angiogenesis score for prognosis assessment in patients with cervical cancer. Anticancer Res 2011;31:2645-2649.
13.
Landt S, Mordelt K, Schwidde I, Barinoff J, Korlach S, Stöblen F, Lichtenegger W, Sehouli J, Kümmel S: Prognostic significance of the angiogenic factors angiogenin, endoglin and endostatin in cervical cancer. Anticancer Res 2011;31:2651-2655.
14.
Koss LG: The Papanicolaou test for cervical cancer detection. A triumph and a tragedy. JAMA 1989;261:737-743.
15.
Shingleton HM, Patrick RL, Johnston WW, Smith RA: The current status of the Papanicolaou smear. CA Cancer J Clin 1995;45:305-320.
16.
Jiang B, Wu GP, Zhao YJ, Wang SC: Transcription expression and clinical significance of TTF-1 mRNA in pleural effusion of patients with lung cancer. Diagn Cytopathol 2008;36:849-854.
17.
Sun Y, Wu GP, Fang CQ, Liu SL: Diagnostic utility of MOC-31, HBME-1 and MOC-31 mRNA in distinguishing between carcinoma cells and reactive mesothelial cells in pleural effusions. Acta Cytol 2009;53:619-624.
18.
Kurusu Y, Yamashita J, Ogawa M: Detection of circulating tumor cells by reverse transcriptase-polymerase chain reaction in patients with resectable non-small-cell lung cancer. Surgery 1999;126:820-826.
19.
Doeberitz MK, Lacroix J: Nucleic acid based techniques for the detection of rare cancer cells in clinical samples. Cancer Metastasis Rev 1999;18:43-64.
20.
Lv M, Wu MZ, Zhao YJ, Yamg D, Wang EH, Wu GP: Expression and clinical significance of lung-specific X protein mRNA in bronchial brushing specimens from patients with or without lung cancer. Respirology 2011;16:1076-1080.
21.
Wang W, Wang S, Song X, Sima N, Xu X, Luo A, Chen G, Deng D, Xu Q, Meng L, Lu Y, Ma D: The relationship between c-FLIP expression and human papillomavirus E2 gene disruption in cervical carcinogenesis. Gynecol Oncol 2007;105:571-577.
22.
Fan YB, Wu X, Fu ZM, Wu GP: Amplification of the human telomerase gene in liquid-based preparations is associated with cervical dysplasia and carcinoma. Int J Gynecol Pathol 2010;29:157-164.
23.
Smith-McCune KK, Weidner N: Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 1994;54:800-804.
24.
Loncaster JA, Cooper RA, Logue JP, Davidson SE, Hunter RD, West CM: Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 2000;83:620-625.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.